Investigating how specific immune cells respond to tuberculosis infection
Role of molecular drivers in memory group 1 CD1-restricted T cell differentiation and Mycobacterium tuberculosis infection
['FUNDING_FELLOWSHIP'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10898724
This study is looking at how certain immune cells help fight tuberculosis, and it's testing new vaccine ideas that could be especially helpful for people with weakened immune systems.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10898724 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of group 1 CD1-restricted T cells in the immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis. The researchers are developing synthetic subunit vaccines that use specific lipid antigens from the bacteria to stimulate these immune cells. By studying how these T cells can be activated and how they contribute to immunity, the research aims to improve vaccine strategies against tuberculosis, especially in individuals who are immunocompromised. The approach includes using genetically modified mice to analyze the immune response and the potential of new vaccine candidates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of tuberculosis infection, particularly those who are immunocompromised or have a history of tuberculosis exposure.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been effectively vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer vaccines against tuberculosis.
How similar studies have performed: Previous research has shown promise in using lipid antigens for vaccine development, indicating that this approach could be a significant advancement in tuberculosis treatment.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MORGUN, EVA — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: MORGUN, EVA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.